{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Scherbakov AM"],"funding":["Russian Science Foundation"],"pagination":["142-152"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9875769"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(1)"],"pubmed_abstract":["The promising antitumor effects of progesterone derivatives have been identified in many studies. However, the specific mechanism of action of this class of compounds has not been fully described. Therefore, in this study, we investigated the antiproliferative and (anti)estrogenic activities of novel pentacyclic derivatives and benzylidenes of the progesterone series. The antiproliferative effects of the compounds were evaluated on hormone-dependent MCF7 breast cancer cells using the MTT test. Estrogen receptor α (ERα) activity was assessed by a luciferase-based reporter assay. Immunoblotting was used to evaluate the expression of signaling proteins. All benzylidenes demonstrated inhibitory effects with IC<sub>50</sub> values below 10 µM, whereas pentacyclic derivatives were less active. T"],"journal":["Investigational new drugs"],"pubmed_title":["Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells."],"pmcid":["PMC9875769"],"funding_grant_id":["19-15-00245"],"pubmed_authors":["Salnikova DI","Mrdjanovic J","Shirinian VZ","Vorontsova SK","Zavarzin IV","Khamidullina AI","Andreeva OE","Jurisic V","Scherbakov AM","Bogdanov FB"],"additional_accession":[]},"is_claimable":false,"name":"Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells.","description":"The promising antitumor effects of progesterone derivatives have been identified in many studies. However, the specific mechanism of action of this class of compounds has not been fully described. Therefore, in this study, we investigated the antiproliferative and (anti)estrogenic activities of novel pentacyclic derivatives and benzylidenes of the progesterone series. The antiproliferative effects of the compounds were evaluated on hormone-dependent MCF7 breast cancer cells using the MTT test. Estrogen receptor α (ERα) activity was assessed by a luciferase-based reporter assay. Immunoblotting was used to evaluate the expression of signaling proteins. All benzylidenes demonstrated inhibitory effects with IC<sub>50</sub> values below 10 µM, whereas pentacyclic derivatives were less active. T","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-05-28T11:32:02.691Z","creation":"2025-04-07T03:19:06.691Z"},"accession":"S-EPMC9875769","cross_references":{"pubmed":["36695998"],"doi":["10.1007/s10637-023-01332-z"]}}